FDA
-
-
-
-
-
-
-
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
-
-
-
-
-
-
-
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
-
-
-
-
-
-
-
Bluejay Diagnostics closes $4.5 million private placement
-
-
-
-
-
-
-
bluejay Diagnostics (BJDX) Provides Mid-Year Business and Corporate Update
-
-
-
-
-
-
-
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
-
-
-
-
-
-
-
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
-
-
-
-
-
-
-
bluejay Diagnostics (BJDX) Regains Nasdaq Compliance
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

